Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: The evidence to date

Pavel A. Levin, Jonathan E. Dowell

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and radiation offer limited benefit, and systemic chemotherapy remains the primary treatment modality for the majority of patients. Vascular endothelial growth factor (VEGF) and its receptor have been recognized as important players in the biology of this disease. Bevacizumab is a monoclonal antibody that binds VEGF and blocks its interaction with the VEGF receptor. Recent studies have shown benefit with the addition of bevacizumab to the combination of cisplatin and pemetrexed in MPM. This combination is now included in the National Comprehensive Cancer Network guidelines (with a category 2A recommendation) as a possible first-line treatment for unresectable MPM in appropriately selected patients. This review discusses the rationale behind the use of bevacizumab in MPM, as well as summarizes the pharmacology, efficacy, safety, and toxicity of bevacizumab across multiple trials. The use of small-molecule inhibitors of angiogenesis in the treatment of MPM is also discussed.

Original languageEnglish (US)
Pages (from-to)2057-2066
Number of pages10
JournalOncoTargets and Therapy
Volume10
DOIs
StatePublished - Apr 7 2017

Fingerprint

Vascular Endothelial Growth Factor Receptor
Pemetrexed
Therapeutics
Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Cisplatin
Neoplasms
Monoclonal Antibodies
Bevacizumab
Malignant Mesothelioma
Pharmacology
Guidelines
Radiation
Safety
Drug Therapy

Keywords

  • Angiogenesis
  • Monoclonal antibody
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma : The evidence to date. / Levin, Pavel A.; Dowell, Jonathan E.

In: OncoTargets and Therapy, Vol. 10, 07.04.2017, p. 2057-2066.

Research output: Contribution to journalReview article

@article{2fc86f590fea43ec9c188683ebe73896,
title = "Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: The evidence to date",
abstract = "Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and radiation offer limited benefit, and systemic chemotherapy remains the primary treatment modality for the majority of patients. Vascular endothelial growth factor (VEGF) and its receptor have been recognized as important players in the biology of this disease. Bevacizumab is a monoclonal antibody that binds VEGF and blocks its interaction with the VEGF receptor. Recent studies have shown benefit with the addition of bevacizumab to the combination of cisplatin and pemetrexed in MPM. This combination is now included in the National Comprehensive Cancer Network guidelines (with a category 2A recommendation) as a possible first-line treatment for unresectable MPM in appropriately selected patients. This review discusses the rationale behind the use of bevacizumab in MPM, as well as summarizes the pharmacology, efficacy, safety, and toxicity of bevacizumab across multiple trials. The use of small-molecule inhibitors of angiogenesis in the treatment of MPM is also discussed.",
keywords = "Angiogenesis, Monoclonal antibody, VEGF",
author = "Levin, {Pavel A.} and Dowell, {Jonathan E.}",
year = "2017",
month = "4",
day = "7",
doi = "10.2147/OTT.S113598",
language = "English (US)",
volume = "10",
pages = "2057--2066",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma

T2 - The evidence to date

AU - Levin, Pavel A.

AU - Dowell, Jonathan E.

PY - 2017/4/7

Y1 - 2017/4/7

N2 - Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and radiation offer limited benefit, and systemic chemotherapy remains the primary treatment modality for the majority of patients. Vascular endothelial growth factor (VEGF) and its receptor have been recognized as important players in the biology of this disease. Bevacizumab is a monoclonal antibody that binds VEGF and blocks its interaction with the VEGF receptor. Recent studies have shown benefit with the addition of bevacizumab to the combination of cisplatin and pemetrexed in MPM. This combination is now included in the National Comprehensive Cancer Network guidelines (with a category 2A recommendation) as a possible first-line treatment for unresectable MPM in appropriately selected patients. This review discusses the rationale behind the use of bevacizumab in MPM, as well as summarizes the pharmacology, efficacy, safety, and toxicity of bevacizumab across multiple trials. The use of small-molecule inhibitors of angiogenesis in the treatment of MPM is also discussed.

AB - Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and radiation offer limited benefit, and systemic chemotherapy remains the primary treatment modality for the majority of patients. Vascular endothelial growth factor (VEGF) and its receptor have been recognized as important players in the biology of this disease. Bevacizumab is a monoclonal antibody that binds VEGF and blocks its interaction with the VEGF receptor. Recent studies have shown benefit with the addition of bevacizumab to the combination of cisplatin and pemetrexed in MPM. This combination is now included in the National Comprehensive Cancer Network guidelines (with a category 2A recommendation) as a possible first-line treatment for unresectable MPM in appropriately selected patients. This review discusses the rationale behind the use of bevacizumab in MPM, as well as summarizes the pharmacology, efficacy, safety, and toxicity of bevacizumab across multiple trials. The use of small-molecule inhibitors of angiogenesis in the treatment of MPM is also discussed.

KW - Angiogenesis

KW - Monoclonal antibody

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=85017513110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017513110&partnerID=8YFLogxK

U2 - 10.2147/OTT.S113598

DO - 10.2147/OTT.S113598

M3 - Review article

C2 - 28435296

AN - SCOPUS:85017513110

VL - 10

SP - 2057

EP - 2066

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -